Phio Pharmaceuticals Corp. (PHIO) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary INTASYL self-delivering siRNA technology. The company operates as a single segment focused on the development of PH-762 (targeting PD-1) and PH-894 (targeting BRD4). As of the filing date, the company has no product revenues and relies on equity financing to fund operations.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,769,000) | $(2,154,000) |
| Operating Expenses | $1,872,000 | $2,209,000 |
| Cash and Cash Equivalents (End of Period) | $13,278,000 | $6,475,000 |
| Net Cash Used in Operating Activities | $(1,275,000) | $(2,011,000) |
| Net Cash Provided by Financing Activities | $9,173,000 | $(4,000) |
| Stockholders' Equity | $12,170,000 | $5,604,000 |
| Weighted Avg. Shares Outstanding | 4,307,264 | 4,580,072 |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $385,000 (18%) compared to Q1 2024, driven by lower operating expenses.
- Expense Reductions: Total operating expenses declined by $337,000. Research and Development (R&D) expenses dropped 23% ($262,000 decrease) due to reduced salary and consulting costs. General and Administrative (G&A) expenses decreased 7% ($75,000 decrease).
- Significant Capital Raise: The company raised approximately $9.17 million in net proceeds from financing activities in Q1 2025, primarily through three registered direct offerings and private placements in January 2025, and the exercise of warrants. This contrasts with negligible financing activity in Q1 2024.
- Liquidity Improvement: Cash balances increased from $5.38 million at year-end 2024 to $13.28 million at March 31, 2025.
- Collaboration Termination: The company terminated its Clinical Co-Development Agreement with AgonOx, Inc. in May 2024. A final payment of $34,320 was made in March 2025 to settle all obligations, with no further expenses recognized for this agreement in Q1 2025.
Outlook, Risks, and Management Commentary
- Clinical Progress: The Phase 1b clinical trial for PH-762 is ongoing. As of the filing, 10 patients have been treated in the first three cohorts, with 4 showing pathologic complete response. Enrollment is expected to complete in Q3 2025. The IND submission for PH-894 has been deferred to prioritize PH-762.
- Going Concern: Management states that current cash resources may not be sufficient to fund operations for at least the next 12 months, raising substantial doubt about the company's ability to continue as a going concern without additional financing.
- Future Funding: The company expects its current cash position (including Q1 2025 proceeds) to fund operations into the second quarter of 2026. However, it anticipates needing substantial additional capital for clinical trials and operations.
- Nasdaq Compliance Risk: The company faces risks regarding continued listing on The Nasdaq Capital Market. It must maintain stockholders' equity of at least $2.5 million (currently $12.2 million) and a minimum bid price of $1.00. A reverse stock split was effected in July 2024; if the bid price falls below $1.00 before July 5, 2025, the company may be ineligible for a grace period to regain compliance via another split.
- Trade Policy Risks: The filing highlights potential adverse impacts from new U.S. trade policies and tariffs (e.g., on imports from Mexico, Canada, and China) which could increase manufacturing costs or disrupt supply chains.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the "second quarter of 2026" funding projection against current burn rates and potential delays in the PH-762 trial.
- Dilution Impact: Review the terms of the Series G, H, and I warrants issued in January 2025, noting the 2:1 warrant-to-share ratio and exercise prices of $3.00, which represent significant potential dilution.
- Nasdaq Status: Monitor the daily closing bid price of PHIO stock to ensure it remains above the $1.00 threshold to avoid immediate delisting risks prior to July 2025.
- Clinical Data: Await the full data readout from the PH-762 Phase 1b trial (expected Q3 2025) to validate the preliminary pathologic complete response rates mentioned.
- Going Concern Disclosure: Confirm if the company has secured additional funding commitments or strategic partnerships to mitigate the "substantial doubt" regarding its ability to continue as a going concern.